2024
Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study
Masri A, Lester S, Stendahl J, Hegde S, Sehnert A, Balaratnam G, Shah A, Fox S, Wang A. Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study. Journal Of The American Heart Association 2024, 13: e030607. PMID: 38591260, PMCID: PMC11262496, DOI: 10.1161/jaha.123.030607.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyKansas City Cardiomyopathy Questionnaire–Overall Summary scoreSymptomatic obstructive hypertrophic cardiomyopathyOutflow tract gradientHypertrophic cardiomyopathyNew York Heart Association class improvementLeft ventricular outflow tract gradientTreatment-emergent adverse eventsSerum NT-proBNP levelsLeft ventricular ejection fractionEffect of mavacamtenIndividual dose titrationNT-proBNP levelsVentricular ejection fractionSerum NT-proBNPSummary scoreLong-term safetyLonger-term treatmentDose titrationEjection fractionNT-proBNPB-blockersReduced doseAdverse eventsInterim results
2023
LONG-TERM SAFETY AND EFFICACY OF MAVACAMTEN IN PATIENTS (PTS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM): UPDATED RESULTS FROM THE PIONEER-OLE STUDY
Masri A, Lester S, Stendahl J, Hegde S, Sehnert A, Balaratnam G, Fox S, Wang A. LONG-TERM SAFETY AND EFFICACY OF MAVACAMTEN IN PATIENTS (PTS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM): UPDATED RESULTS FROM THE PIONEER-OLE STUDY. Journal Of The American College Of Cardiology 2023, 81: 346. DOI: 10.1016/s0735-1097(23)00790-8.Peer-Reviewed Original ResearchHypertrophic cardiomyopathySymptomatic obstructive hypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathyPatients